Abstract:3852 Chan su, the dried toad venom or the dried secretion from the skin glands of Bufo bufo gargarizans Cantor or B. melanotictus Schneider, has long been used as a therapeutic agent for cancer treatment in China and other Asian countries. Huachansu, an injectable form of Chan su, is a sterilized hot water extract of dried toad skin. Since 1991, huachansu has been officially approved as a regimen for treatment of cancer in China. However, the selectivity and mechanism of anti-cancer activity of huachansu have not been fully elucidated. The goals of our current study were to investigate the cytotoxicity of huachansu alone as well as the polar and non-polar compartments of huachansu and cardiac glycosides derived from huachansu against various cancer cells. In addition, we explored mechanisms associated with this extract’s antiproliferative activity. The inhibitory effects of three different lots of huachansu were tested in four different human cell lines including hepatoma (Hep 3B), colon (HT29), pancreatic (Panc-1) and melanoma (BRO) cells. The relative growth inhibitory activity on the growth of cancer cells for all three lots of huachansu was ranked as Panc-1 > HT29 > BRO > Hep3B cells. The inhibitory effect of the non-polar fraction (lipid soluble) of huachansu was much stronger than that of the polar compartment (water soluble) with IC50 of 1.75 mg /ml versus 31.25 mg (raw material)/ml, respectively. These data suggest that huachansu’s antitumor activity is mainly attributed to the lipid-soluble components. Because cardiac glycosides are one of the lipid soluble components in huachansu, we next tested the relative cytotoxicity of three different cardiac glycosides derived from huachansu, including bufalin, cinobufagin, and resibufogenin against BRO cells. The IC50 values of bufalin, cinobufagin, and resibufogenin in BRO cells were 16.7, 20.1 and 700 ng/ml, respectively. When BRO cells were treated with huachansu (1 to 25 mg/ml) for 24 hr, huachansu induced cell cycle arrest in the G2/M-phase. Furthermore, huachansu as well as bufalin down-regulated Bcl-2 expression, yet up-regulated BAX protein in BRO cells in a concentration-dependent manner. In addition, our preliminary data also demonstrated that huachansu (10 mg/ml) significantly reduced B23 (neucleophosmin), pAKT and STAT3 expression. Concomitantly, it up-regulated several cell signaling pathways such as SRC, MAPK, and Raf, which is attributed to the stress-mediated cell response of huachansu cardiac glycosides. Taken together, these results suggest that cardiac glycosides, such as bufalin, are responsible for huachansu induced cell death in BRO cells. Whether other components in huachansu also contribute to its anti-proliferative activity requires further investigation. This research was supported in part by NCI R21 CA108084-01, International Center of TCM for Cancer.

Huachansu, Containing Cardiac Glycosides, Enhances Radiosensitivity of Human Lung Cancer Cells.

Silencing of Heat Shock Protein 27 Increases the Radiosensitivity of Non‑small Cell Lung Carcinoma Cells.

Efficacy and Safety of Huachansu as an Adjuvant Therapy for Non-Small Cell Lung Cancer: An Overview of Systematic Reviews and Meta-Analyses

Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities

Use of cellular metabolomics and lipidomics to decipher the mechanism of Huachansu injection-based intervention against human hepatocellular carcinoma cells

The Dual PPARα/γ Ligand TZD18 Inhibits Cell Growth and Induces Apoptosis in Human Bcr-Abl Positive CML Cell Lines >in Vitro

Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft

Modulating pancreatic cancer microenvironment: The efficacy of Huachansu in mouse models via TGF-β/Smad pathway

Huachansu Capsule Inhibits the Proliferation of Human Gastric Cancer Cells Via Akt/mTOR Pathway.

Peer Review #1 of "radiosensitization Effect of Hsa-Mir-138-2-3p on Human Laryngeal Cancer Stem Cells (V0.2)"

Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation

Phase Ⅰ Study of Huachansu in Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, and Pancreatic Cancer: a Preliminary Report

PUB045 Anti-Tumor Effect of Honokiol in Lung Squamous Cell Carcinoma

Radiosensitization effect of hsa-miR-138-2-3p on human laryngeal cancer stem cells.

Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Nonsmall-Cell Lung Cancer, or Pancreatic Cancer

[Mechanism of Huachansu Injection against colorectal cancer based on network pharmacology and cellular experimental]

A UPLC-QTOF/MS-based hepatic tissue metabolomics approach deciphers the mechanism of Huachansu tablets-based intervention against hepatocellular carcinoma

Danshensu, a major water-soluble component of Salvia miltiorrhiza, enhances the radioresponse for Lewis Lung Carcinoma xenografts in mice

Identification of potential anti-tumor targets and mechanisms of HuaChanSu injection using network pharmacology and cytological experiments in Breast cancer

Radiosensitizing effects of cyclooxygenase-2 selective inhibitor LM-1685 on A549 human lung adenocarcinoma cells

Ginsenoside Rg5 enhances the radiosensitivity of lung adenocarcinoma via reducing HSP90-CDC37 interaction and promoting client protein degradation